Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Tirelizumab Combined with Gemcitabine and Cisplatin (GPLET) in Advanced Cholangiocarcinoma
NCT05532059Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, tislelizumab in cholangiocarcinoma (CCA), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Jan 2022; status: recruiting.
02
Drugs
lenvatinibtislelizumab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05532059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532059.